Anitocabtagene autoleucel (anito-cel), an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, was successfully manufactured for the majority of participants with relapsed or refractory or newly diagnosed multiple myeloma in the iMMagine-3 and GEM-AnitoFIRST trials, according to a poster presented at the 2026 ASCO Annual Meeting.
“The anito-cel CAR T-cell manufacturing process has been optimized by leveraging the learnings from the robust development process of another CAR T-cell therapy, axicabtagene ciloleucel (axi-cel),” said lead author, Krina Patel, MD, MSc, of the University of Texas MD Anderson Cancer Center in Houston.
The anito-cel analysis covered 104 patients enrolled and leukapheresed in iMMagine-3 or GEM-AnitoFirst from September 2024 to October 2025. Anito-cel lots were successfully manufactured for all patients, and 101 out of 102 lots were manufactured successfully on the first pass. The median turnaround time from leukapheresis to quality release of final anito-cel product for the 101 released lots was 18 days (interquartile range, 17-20).
“Our results demonstrate rapid and reliable anito-cel manufacturing for multiple myeloma clinical trials globally, with high manufacturing success rates and consistent turnaround times. These results were consistent with axi-cel manufacturing outcomes and highlight the importance of leveraging axi-cel manufacturing experience in the development of anito-cel,” Dr. Patel and colleagues said.
Leave feedback about this